|
|
|
by hernews
Posted: Tue., August 5, 2008, 11:56 am
|
|
|
TUESDAY, Aug. 5 (HealthDay News) -- A new tool for diagnosing anemia related to chronic illness and diseases of iron overload has been developed by U.S. researchers.
Both anemia and iron overload have various causes.
"It is hard to diagnose the anemia of chronic disease. Having an assay for hepcidin would make it much easier, and it would also help in diagnosing iron overload diseases," study senior author Jerry Kaplan, a professor of pathology and assistant vice president for research at the University of Utah Health Sciences, said in a university news release.
|
|
|
|
|
|
|
by hernews
Posted: Tue., August 5, 2008, 09:34 am
|
|
|
TUESDAY, Aug. 5 (HealthDay News) -- A new tool for diagnosing anemia related to chronic illness and diseases of iron overload has been developed by U.S. researchers.
Both anemia and iron overload have various causes.
"It is hard to diagnose the anemia of chronic disease. Having an assay for hepcidin would make it much easier, and it would also help in diagnosing iron overload diseases," study senior author Jerry Kaplan, a professor of pathology and assistant vice president for research at the University of Utah Health Sciences, said in a university news release.
|
|
|
|
|
|
|
by hernews
Posted: Thu., July 31, 2008, 12:25 pm
|
|
|
THURSDAY, July 31 (HealthDay News) -- A new and potentially better source of platelets (clot-forming blood cells) for transfusion has been identified by Japanese researchers.
Platelets can drop to dangerously low levels in people with anemia and in cancer patients undergoing chemotherapy. To boost platelet levels, doctors filter platelets from donated blood. However, this approach may increase the risk of transmitting blood infections and cause other side effects in patients who require frequent transfusions, according to background information in the study.
|
|
|
|
|
|
|
by hernews
Posted: Thu., July 31, 2008, 10:27 am
|
|
|
Labels on the anemia drugs Aranesp and Procrit must be changed in a way that could limit their use in treating cancer patients, the U.S. Food and Drug Administration says.
It's the first time the FDA has used its authority under a 2007 law that gave the agency the power to order changes in a drug's prescribing information, The New York Times reported. Before the new law, the FDA could only negotiate with drug makers to change labels.
Amgen makes both Aranesp and Procrit, but Procrit is sold under license by Johnson & Johnson.
|
|
|
|
|
|
|
by alpohlman
Posted: Sun., June 15, 2008, 11:56 am
|
|
|
|
|
|
|
|
|
|
|
|
